Low-dose estradiol for climacteric symptoms in Japanese women: A randomized, controlled trial

Climacteric

Volumn 12, Issue 4, 2009, Pages 319-328

  Honjo, H ^a   Taketani, Y ^b  

^a Aiseikai Yamashina Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Climacteric symptoms; Japanese; Low dose; Oral estradiol; Ultra low dose

Indexed keywords

ESTRADIOL; FOLLITROPIN; PLACEBO;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BREAST ENGORGEMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; ENDOMETRIUM CARCINOMA; FEMALE; HOT FLUSH; HUMAN; JAPANESE; JOINT STIFFNESS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; OVARIECTOMY; OVARY DISEASE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; UTERUS BLEEDING; VAGINA DISCHARGE;

ADULT; BODY MASS INDEX; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HOT FLASHES; HUMANS; JAPAN; MENOPAUSE; MIDDLE AGED; OVARIECTOMY; PLACEBOS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SWEATING; VAGINAL DISEASES;

EID: 70350610907     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802657888     Document Type: Article

References (19)

1. The Japan Menopause Society. Views about the 'Report on early termination of estrogen monotherapy in WHI' and the current concept of HRT in Japan. Jpn Menopause Soc 2004:April; 120-123
2. Naftolin F, Schneider HP, Sturdee DW; Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond: Position Statement by the Executive Committee of the International Menopause Society. Climacteric 2004;7:8-11
3. Board of the International Menopause Society, Pines A, Sturdee DW, BirkhÄ user MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-194 (Pubitemid 46752441)
4. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11-33
5. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:168-182
6. Tan D, Darmasetiawan S, Haines CJ, et al. Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter. Climacteric 2006;9: 146-151
7. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44 (Pubitemid 43192860)
8. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804
9. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365 (Pubitemid 43244325)
10. Hodis HN, Mack WJ. Postmenopausal hormone therapy in clinical perspective. Menopause 2007;14:944-957
11. BirkhÄ user MH, Panay N, Archer DF, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108-123
12. Mizuguchi H, Fujimoto S, Sato K, et al. Phase II clinical study of RG83933 transdermal estradiol delivery system: dose-finding study. Rinsho Hyoka 1997;25:23-42
13. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J-C. Initial 17bestradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731
14. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17b-estradiol. Menopause 2000;7:310-317
15. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:123-131
16. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17b-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110:771-779
17. Haines CJ, Xing SM, Park KH, Holinka CF, Ausmanas MK. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitas 2005;52:264-276
18. Tan D, Haines CJ, Limpaphayom KK, Holinka CF, Ausmanas MK. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia Menopause (PAM) study. Maturitas 2005;52:35-51
19. Limpaphayom KK, Darmasetiawan MS, Hussain RI, Burriss SW, Holinka CF, Ausmanas MK. Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Climacteric 2006;9:204-214